ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of
resuscitation devices and related software solutions, announced today
that the first planned review of data related to patient enrollment in
the CIRC (Circulation Improving Resuscitation Care) Trial by the trial
Data Safety Monitoring Board (DSMB) has been completed and the trial is
proceeding with patient enrollment as originally designed.
“As the economy improves we look for the
growth of the AutoPulse to accelerate.”
Data from the international trial that is testing the effectiveness of
the FDA-cleared AutoPulse® Non-invasive Cardiac Support Pump,
in comparison to manual chest compressions alone, was fully reviewed by
the Data Safety Monitoring Board. The Board, which consists of several
physicians and a statistician, is responsible for ensuring the trial is
proceeding safely and in accordance with protocols, and has the
authority to halt the trial. If the Data Safety Monitoring Board were to
have any concerns about the safety of the trial, the Board would be
required to take action to insure patient safety and/or protocol
adherence. More than 700 cases from the two arms of the trial were
reviewed.
The principal investigator for the trial is Lars Wik, M.D., Ulleval
University, Oslo, Norway. Dr. Wik and colleagues from Houston, Texas;
Fox Valley Region, Wisconsin; Hillsborough County, Florida; Vienna,
Austria; and Nijmegen, The Netherlands, are conducting the research into
whether the AutoPulse-integrated chest compressions are superior or
equivalent to manual compressions alone for patients suffering cardiac
arrests tied to heart conditions. Each site has gone through extensive
training around very strict protocols established for the trial,
including proper use of the AutoPulse.
“We are pleased with the significant progress the CIRC Trial is making.
We note that an earlier trial of the AutoPulse, ‘ASPIRE’, was halted
prematurely after its first review due to futility and concerns about
safety, and if similar issues had been identified with CIRC, the DSMB
would have halted enrollment,” said Richard A. Packer, Chairman and
Chief Executive Officer of ZOLL. “Instead, we got a clean check-up and
are continuing ahead in this important effort.”
“While some clinicians are waiting for the results of this trial to
validate the contribution mechanical CPR can make to improving outcomes
from sudden cardiac death, recent reports presented at the American
Heart Association Resuscitation Science Symposium add to the continuing
science supporting the AutoPulse. A presentation from St. Charles
County, Missouri showed a marked likelihood of return of spontaneous
circulation in cardiac arrest patients treated with AutoPulse, and data
from a Statewide California Registry showed the risk of adverse events
associated with the AutoPulse to be no greater than with manual CPR
while improving return of spontaneous circulation by forty-five
percent,” Mr. Packer added. “As the economy improves we look for the
growth of the AutoPulse to accelerate.”
The AutoPulse has been commercially available for over four years and is
in use worldwide. It is manufactured by ZOLL Medical Corporation, which
is the CIRC trial's sponsor.